BR0008584A - 2-indolil(n-substituìdo)carbonildipeptìdeos modificados no terminal c como inibidores da famìlia ice/ced-3 das cisteìna proteases - Google Patents

2-indolil(n-substituìdo)carbonildipeptìdeos modificados no terminal c como inibidores da famìlia ice/ced-3 das cisteìna proteases

Info

Publication number
BR0008584A
BR0008584A BR0008584-7A BR0008584A BR0008584A BR 0008584 A BR0008584 A BR 0008584A BR 0008584 A BR0008584 A BR 0008584A BR 0008584 A BR0008584 A BR 0008584A
Authority
BR
Brazil
Prior art keywords
ice
indolyl
inhibitors
family
substituted
Prior art date
Application number
BR0008584-7A
Other languages
English (en)
Inventor
Donald S Karanewsky
Xu Bai
Original Assignee
Idun Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idun Pharmaceuticals Inc filed Critical Idun Pharmaceuticals Inc
Publication of BR0008584A publication Critical patent/BR0008584A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)

Abstract

"2-INDOLIL( N-SUBSTITUíDO )CARBONILDIPEPTíDEOS MODIFICADOS NO TERMINAL C COMO INIBIDORES DA FAMìLIA ICE/CED-3 DAS CISTEìNA PROTEASES". A presente invenção refere-se a novos compostos inibidores de indol ( N-substituído ) ICE/ced-3. A invenção refere-se também a composições farmacêuticas de tais compostos de indol, e ainda ao uso de tais composições no tratamento de pacientes sofrendo de doenças inflamatórias, autoimunes e neurodegenerativas, para a prevenção de lesão isquêmica.
BR0008584-7A 1999-03-02 2000-03-02 2-indolil(n-substituìdo)carbonildipeptìdeos modificados no terminal c como inibidores da famìlia ice/ced-3 das cisteìna proteases BR0008584A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26081699A 1999-03-02 1999-03-02
US09/345,724 US6184244B1 (en) 1996-12-16 1999-06-30 C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
PCT/US2000/005648 WO2001000658A1 (en) 1999-03-02 2000-03-02 C-terminal modified (n-substituted)-2-indolylcarbonyldipeptides as inhibitors of the ice/ced-3 family of cysteine proteases

Publications (1)

Publication Number Publication Date
BR0008584A true BR0008584A (pt) 2002-06-11

Family

ID=26948195

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008584-7A BR0008584A (pt) 1999-03-02 2000-03-02 2-indolil(n-substituìdo)carbonildipeptìdeos modificados no terminal c como inibidores da famìlia ice/ced-3 das cisteìna proteases

Country Status (12)

Country Link
US (3) US6184244B1 (pt)
EP (1) EP1159291A1 (pt)
JP (1) JP2003503421A (pt)
KR (1) KR20020004956A (pt)
CN (1) CN1345332A (pt)
AU (1) AU3721800A (pt)
BR (1) BR0008584A (pt)
CA (1) CA2365341A1 (pt)
HK (1) HK1042502A1 (pt)
MX (1) MXPA01008919A (pt)
NZ (1) NZ513885A (pt)
WO (1) WO2001000658A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US6610683B2 (en) * 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6184244B1 (en) * 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6184210B1 (en) * 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
EP1042287B1 (en) * 1997-12-24 2005-04-20 Aventis Pharma Deutschland GmbH Indole derivatives as inhibitors of factor xa
EP1064298B1 (en) * 1998-03-19 2008-10-08 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
US7053056B2 (en) * 1998-07-02 2006-05-30 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
CN1176941C (zh) 1999-04-09 2004-11-24 西托维亚公司 Caspase抑制剂及其应用
MXPA02002038A (es) 1999-08-27 2002-10-31 Cytovia Inc Acidos alfa-hidroxi substituidores inhibidores de la caspasa y uso de los mismos.
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
US6693134B2 (en) 2001-05-29 2004-02-17 Chemokine Therapeutics Corporation Bicyclic aromatic chemokine receptor ligands
AU2003211052A1 (en) * 2002-02-11 2003-09-04 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
US7960398B2 (en) * 2002-04-19 2011-06-14 Vertex Pharmaceuticals Incorporated Regulation of TNF-alpha
US20060205771A1 (en) * 2002-09-25 2006-09-14 Mark Noble Caspase inhibitors as anticancer agents
PE20050159A1 (es) * 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
WO2004108671A1 (en) * 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
CA2545733A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring il-18
ES2532433T3 (es) * 2004-03-12 2015-03-26 Vertex Pharmaceuticals Incorporated Proceso y productos intermedios para la preparación de inhibidores de la acetal caspasa aspártica
CA2566362C (en) 2004-05-15 2013-09-10 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
CN1980658A (zh) * 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 治疗自身炎性疾病的ice抑制剂
ES2380632T3 (es) 2004-11-24 2012-05-17 Vertex Pharmceuticals Incorporated Derivados de ácido3-(2-(3-ACILAMINO-2-OXO-2H-PIRIDIN)-ACETILAMINO)-4-OXO-PENTANOICO y su uso como inhibidores de caspasas
CN101268084A (zh) * 2005-07-28 2008-09-17 沃泰克斯药物股份有限公司 天冬氨酸特异性半胱氨酸蛋白酶抑制剂前体药物
US20140309172A1 (en) 2010-11-05 2014-10-16 Dagmar Ringe Ice inhibiting compounds and uses thereof
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
US11434212B2 (en) 2017-01-23 2022-09-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic compound as a caspase inhibitor
CN111757871B (zh) 2018-03-13 2022-04-12 正大天晴药业集团股份有限公司 一种Caspase抑制剂的结晶

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965296A (en) 1989-03-15 1990-10-23 No Fire Engineering, Inc. Intumescent fire-retardant and electrically-conductive coating material
AU6056790A (en) 1989-07-26 1991-03-11 Optec Co., Ltd. Light-emitting display device and light-emitting display system
US5187411A (en) 1989-09-01 1993-02-16 Systems And Service International, Inc. Discharge lamp life and lamp lumen life-extender module, circuitry, and methodology
AU7775991A (en) 1990-04-04 1991-10-30 Immunex Corporation Interleukin 1beta protease
EP0519748B1 (en) 1991-06-21 1998-09-02 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
DE4121608A1 (de) 1991-06-29 1993-01-07 Cts Consulting Gmbh Verfahren und einrichtung zum enteisen von fahrbahnen
EP0533226A3 (en) 1991-08-16 1993-08-18 Merck & Co. Inc. Novel chromophore containing compounds
US6348570B1 (en) 1991-08-16 2002-02-19 Merck & Co., Inc. Chromophore containing compounds and their use in determining interleukin-1β convertase activity
EP1378573A1 (en) 1991-08-30 2004-01-07 Vertex Pharmaceuticals Incorporated Interleukin 1 beta protease and interleukin 1 beta protease inhibitors
GB9123326D0 (en) * 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
WO1993014777A1 (en) 1992-01-31 1993-08-05 Merck & Co., Inc. PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
US5246113A (en) 1992-02-11 1993-09-21 Riverwood International Corporation Carrier for stacked articles
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
ATE167872T1 (de) * 1992-07-31 1998-07-15 Pfizer Peptide aus derivaten der 4-amino-2.2.-difluoro-3-oxo-1.6-hexandisäure als wirkstoffe gegen entzündungen
US5514694A (en) * 1992-09-21 1996-05-07 Georgia Tech Research Corp Peptidyl ketoamides
EP0618223A3 (en) 1993-03-08 1996-06-12 Sandoz Ltd Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents.
TW494094B (en) 1993-04-29 2002-07-11 Vertex Pharma Peptide analogs as irreversible interleukin-1β protease inhibitors and pharmaceutical compositions comprising the same
US5462939A (en) 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
AU7714594A (en) 1993-08-13 1995-03-14 Merck & Co., Inc. Substituted ketone derivatives as inhibitors of interleukin-1beta converting enzyme
US5486623A (en) * 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5498616A (en) * 1994-11-04 1996-03-12 Cephalon, Inc. Cysteine protease and serine protease inhibitors
US5556879A (en) 1995-03-01 1996-09-17 Rhone Merieux, Inc. Aqueous spectinomycin borate solutions
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US6610683B2 (en) * 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6200969B1 (en) * 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
IL125190A (en) * 1996-09-12 2003-01-12 Idun Pharmaceuticals Inc Tricyclic compounds for the inhibition of the ice/ced-3 protease family of enzymes and pharmaceutical compositions containing the same
US6531467B2 (en) * 1996-09-12 2003-03-11 Idun Pharmaceuticals, Inc. Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US5869519A (en) * 1996-12-16 1999-02-09 Idun Pharmaceuticals, Inc. C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6184244B1 (en) * 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6432628B1 (en) 1997-08-26 2002-08-13 Thomas Jefferson University Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use
AU750170B2 (en) 1997-10-30 2002-07-11 Human Genome Sciences, Inc. Caspase-14 polypeptides
CA2335099A1 (en) 1998-07-17 2000-01-27 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw New caspase homologue

Also Published As

Publication number Publication date
US20030119748A1 (en) 2003-06-26
KR20020004956A (ko) 2002-01-16
NZ513885A (en) 2001-09-28
WO2001000658A1 (en) 2001-01-04
US6489353B2 (en) 2002-12-03
EP1159291A1 (en) 2001-12-05
CN1345332A (zh) 2002-04-17
HK1042502A1 (zh) 2002-08-16
US20020025935A1 (en) 2002-02-28
US6184244B1 (en) 2001-02-06
JP2003503421A (ja) 2003-01-28
CA2365341A1 (en) 2001-01-04
MXPA01008919A (es) 2002-08-30
AU3721800A (en) 2001-01-31

Similar Documents

Publication Publication Date Title
BR0008584A (pt) 2-indolil(n-substituìdo)carbonildipeptìdeos modificados no terminal c como inibidores da famìlia ice/ced-3 das cisteìna proteases
MXPA00013014A (es) Dipe`tidos de oxamilos modificados en el extremo carboxi como inhibidores de la familia ice/ced-3 de proteasas de cisteinas.
WO2003072528A3 (en) (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
SG158733A1 (en) Cell adhesion inhibitors
IL128940A0 (en) C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases and pharmaceutical compositions containing them
EA199700135A1 (ru) Ингибиторы клеточной адгезии
NO20011968L (no) (Substituerte)acyl dipeptidyl-inhibitorer av ICE/ced-3 familien av cysteinproteaser
YU46097A (sh) Nova klasa estara i njihove farmaceutske smeše
ATE217321T1 (de) Aromatische heterocyclische derivate als enzyminhibitoren
EA200100872A1 (ru) Композиция валдекоксиба
ATE267168T1 (de) Beta-alanin-derivate als zell-adhäsions- inhibitoren
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
HUP0100669A3 (en) Peptide derivatives as serine protease inhibitors, their use and pharmaceutical compositions comprising thereof
MX9704684A (es) Derivados de glicina n-sustituidos, como inhibidores del factor xa.
AU4583597A (en) Novel tricyclic compounds for the inhibition of the ice/ced-3 protease family of enzymes
WO2002057298A3 (en) C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
ATE229514T1 (de) Macrocyclische verbindungen als metallproteaseinhibitoren
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
EA200200063A1 (ru) Химера il6ril6 для лечения нейродегенеративных заболеваний
WO2001079162A3 (en) INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES
DE50002304D1 (en) Tyrosin- und tryptophanhaltige peptide als antioxidantien
ES2131468A1 (es) Uso de la melatonina en el tratamiento de las enfermedades neurodegenerativas.
MX9606566A (es) Derivados 3-amina-2-0xo-1-piperidin aceticos como inhibidores de enzima.

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]